share_log

Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering

Aimei Health Technology Co., Ltd Announces Pricing of $60 Million Initial Public Offering

爱美健康科技有限公司宣布6000万美元首次公开募股的定价
GlobeNewswire ·  2023/12/01 17:28

NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (NASDAQ: AFJKU, the "Company") announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The units are expected to be listed on The NASDAQ Global Market ("NASDAQ") and trade under the ticker symbol "AFJKU" beginning December 4, 2023. Each unit consists of one ordinary share and one right. Each right entitles the holder thereof to receive one-fifth (1/5) of one ordinary share upon the consummation of an initial business combination. No fractional rights will be issued upon separation of the units. As a result, 5 rights are needed to receive one ordinary share at the closing of the initial business combination. Once the securities comprising the units begin separate trading, the common stock and rights are expected to be listed on NASDAQ under the symbols "AFJK" and "AFJKR", respectively.

纽约,2023年12月1日(GLOBE NEWSWIRE)——艾美健康科技股份有限公司(纳斯达克股票代码:AFJKU,以下简称 “公司”)今天宣布,其首次公开发行600万套的定价为每单位10美元。这些单位预计将于2023年12月4日起在纳斯达克全球市场(“纳斯达克”)上市,股票代码为 “AFJKU”。每个单位由一股普通股和一股权利组成。每项权利都使该权利的持有人有权在初始业务合并完成后获得普通股的五分之一(1/5)。单位分离后将不发放任何部分权利。因此,在初始业务合并结束时,需要5股权利才能获得一股普通股。一旦构成这些单位的证券开始单独交易,普通股和股票预计将分别在纳斯达克上市,股票代码为 “AFJK” 和 “AFJKR”。

The underwriters have been granted a 45-day option to purchase up to an additional 900,000 units offered by the Company to cover over-allotments, if any.

承销商已获得45天的选择权,可以额外购买公司提供的最多90万套单位,以弥补超额配股(如果有)。

The offering is expected to close on December 6, 2023, subject to customary closing conditions.

此次发行预计将于2023年12月6日结束,但须遵守惯例成交条件。

Spartan Capital Securities, LLC acted as sole book running manager in the offering. Loeb & Loeb LLP is serving as legal counsel to the Company. Hunter, Taubman Fischer & Li LLC is serving as legal counsel to Spartan Capital Securities, LLC.

斯巴达资本证券有限责任公司担任本次发行的唯一账面经理。Loeb & Loeb Llp担任该公司的法律顾问。Hunter、Taubman Fischer & Li LLC担任斯巴达资本证券有限责任公司的法律顾问。

ARC Group Limited acted as financial advisor to the Company.

ARC集团有限公司担任该公司的财务顾问。

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 30, 2023. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Spartan Capital Securities, LLC, 45 Broadway, 19th Floor, New York, NY 10006. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.

美国证券交易委员会于2023年11月30日宣布与这些证券有关的注册声明生效。此次发行仅通过招股说明书进行,招股说明书的副本可通过联系位于纽约州纽约百老汇45号19楼的斯巴达资本证券有限责任公司获取。注册声明的副本可以通过美国证券交易委员会的网站www.sec.gov获取。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽买入要约,在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前,此类要约、招标或出售是非法的州或司法管辖区也不得出售这些证券。

About Aimei Health Technology Co., Ltd

关于爱美健康科技股份有限公司

Aimei Health Technology Co., Ltd is a blank check company newly incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although it is the Company's intention to pursue prospective targets that are focused on healthcare innovation.

Aimei Health Technology Co., Ltd是一家作为开曼群岛豁免公司新成立的空白支票公司,其目的是与一个或多个企业或实体进行合并、股份交换、资产收购、股份购买、资本重组、重组或类似的业务合并。尽管公司打算追求专注于医疗创新的潜在目标,但公司确定潜在目标业务的努力将不仅限于特定的行业或地理区域。

Forward-Looking Statements

前瞻性陈述

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

本新闻稿包括涉及风险和不确定性的前瞻性陈述。前瞻性陈述是非历史事实的陈述。此类前瞻性陈述存在风险和不确定性,这可能导致实际结果与前瞻性陈述不同。公司明确声明不承担任何义务或承诺公开发布此处包含的任何前瞻性陈述的任何更新或修订,以反映公司对其预期的任何变化或任何陈述所依据的事件、条件或情况的任何变化。

Contact:
Juan Fernandez Pascual
Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022

联系人:
胡安·费尔南德斯·帕斯夸尔
爱美健康科技股份有限公司
东 53 街 10 号,套房 3001
纽约州纽约 10022


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发